Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

Clinical trial NCT00446654 · COMPLETED

Trial details

NCT number: NCT00446654
Sponsor: Progen Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Age Related Macular Degeneration

Start date: 2007-04-01
Primary completion: 2007-10-01
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.